230 related articles for article (PubMed ID: 36840958)
21. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
22. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
23. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
24. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
[TBL] [Abstract][Full Text] [Related]
25. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
26. Tirzepatide: A Review in Type 2 Diabetes.
France NL; Syed YY
Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
[TBL] [Abstract][Full Text] [Related]
27. Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
Viljoen A; Pantalone KM; Galindo RJ; Cui X; Huh R; Hemmingway A; Fernández Landó L; Patel H
Diabetes Ther; 2023 May; 14(5):925-936. PubMed ID: 37000390
[TBL] [Abstract][Full Text] [Related]
28. Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
Zeitler P; Galindo RJ; Davies MJ; Bergman BK; Thieu VT; Nicolay C; Allen S; Heine RJ; Lee CJ
Diabetes Care; 2024 Jun; 47(6):1056-1064. PubMed ID: 38639997
[TBL] [Abstract][Full Text] [Related]
29. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
Osumili B; Fan L; Paik JS; Pantalone KM; Ranta K; Sapin H; Tofé S
Diabetes Res Clin Pract; 2024 Jun; 212():111717. PubMed ID: 38777128
[TBL] [Abstract][Full Text] [Related]
30. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
[TBL] [Abstract][Full Text] [Related]
32. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.
Igarashi A; Hunt B; Wilkinson L; Langer J; Pollock RF
Adv Ther; 2020 Oct; 37(10):4446-4457. PubMed ID: 32870471
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
Vadher K; Patel H; Mody R; Levine JA; Hoog M; Cheng AY; Pantalone KM; Sapin H
Diabetes Obes Metab; 2022 Sep; 24(9):1861-1868. PubMed ID: 35589616
[TBL] [Abstract][Full Text] [Related]
34. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
[TBL] [Abstract][Full Text] [Related]
35. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
Tall Bull S; Nuffer W; Trujillo JM
J Diabetes Complications; 2022 Dec; 36(12):108332. PubMed ID: 36375235
[TBL] [Abstract][Full Text] [Related]
36. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
Patel H; Khunti K; Rodbard HW; Bajaj HS; Bray R; Kindracki Z; Rodríguez Á
Diabetes Obes Metab; 2024 Feb; 26(2):473-481. PubMed ID: 37853960
[TBL] [Abstract][Full Text] [Related]
38. The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
Liebisch-Rey H; Suarez-Chacon AM; Fuentes YV; Blanco J; Kock J; Lechtig-Wassermann S; Bustos RH
F1000Res; 2023; 12():914. PubMed ID: 38125558
[TBL] [Abstract][Full Text] [Related]
39. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.
De Block C; Bailey C; Wysham C; Hemmingway A; Allen SE; Peleshok J
Diabetes Obes Metab; 2023 Jan; 25(1):3-17. PubMed ID: 35929488
[TBL] [Abstract][Full Text] [Related]
40. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
Boye KS; Sapin H; Dong W; Williamson S; Lee CJ; Thieu VT
Diabetes Ther; 2023 Nov; 14(11):1867-1887. PubMed ID: 37668888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
